Genetically Engineered Probiotics: Design, Therapeutics, and Clinical Translation

Area of Science:

• Microbiology
• Synthetic Biology
• Biotechnology

Background:

• Conventional probiotics face challenges with transient colonization and variability.
• Genetically engineered probiotics (GEPs) leverage advanced molecular tools to overcome these limitations.
• CRISPR/Cas editing, gene circuits, and biosensors are key technologies in GEP development.

Purpose of the Study:

• To review engineering toolkits, chassis selection, and biocontainment for GEPs.
• To discuss translational requirements under CMC/GMP and regulatory considerations.
• To highlight advancements and future directions for GEPs in clinical settings.

Main Methods:

• Narrative review of current GEP engineering strategies and standards (e.g., SEVA).
• Analysis of chassis selection criteria (e.g., E. coli Nissle 1917, L. lactis).
• Examination of biocontainment, CMC/GMP frameworks, and regulatory pathways.

Main Results:

• Examples like IL-10 secreting L. lactis and phenylalanine-metabolizing strains (SYNB1618/SYNB1934) demonstrate target engagement and safety.
• Advancements include predefined pharmacodynamics, functional durability, and monitoring of shedding/HGT.
• Systems modeling (GEM/ABM) aids rational GEP design.

Conclusions:

• GEPs represent programmable therapeutics with potential for significant clinical impact.
• Successful adoption requires demonstrating durable efficacy, long-term safety, and navigating regulatory landscapes.
• Genomic-microbiome insights can inform patient stratification for GEP therapies.